Effectiveness and Safety of Mepolizumab in Allergic Bronchopulmonary Aspergillosis ( <scp>ABPA</scp> ): Real‐World Experience From a Chinese Retrospective Case Series
Summary Mepolizumab improved lung function and reduced airway eosinophilia in ABPA. Treatment enabled substantial steroid tapering without safety concerns.
Authors
- Liang Dong (ORCID: https://orcid.org/0000-0001-7707-9982)
- Qian Qi (ORCID: https://orcid.org/0000-0002-5813-3194)
- Mingxiao Wu (ORCID: https://orcid.org/0009-0004-1734-8588)
- Xu Li (ORCID: https://orcid.org/0009-0005-9184-5985)
- Ruichen Du
- Yangyang Qu (ORCID: https://orcid.org/0000-0003-1285-8584)
- Lili Zhi (ORCID: https://orcid.org/0000-0001-5664-9974)
- H Li (ORCID: https://orcid.org/0009-0000-1237-3013)
- Jingjing Wang (ORCID: https://orcid.org/0000-0003-4798-8960)
- Pei Liu (ORCID: https://orcid.org/0000-0002-4897-2736)
- Tingting Gao (ORCID: https://orcid.org/0000-0001-9704-1682)
Institutions
- Shandong Provincial Hospital (CN)
- Shandong Provincial QianFoShan Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Clinical & Experimental Allergy
- Published
- 2025-12-14
- DOI
- https://doi.org/10.1111/cea.70199
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00